About Catalyst Pharmaceuticals (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. The company is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet. It has license agreements with Northwestern University, New York University and the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CPRX
CUSIPN/A
Phone305-420-3200
Debt
Debt-to-Equity RatioN/A
Current Ratio20.00%
Quick Ratio20.00%
Price-To-Earnings
Trailing P/E Ratio-12.02
Forward P/E Ratio-7.03
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.79 per share
Price / Book3.20
Profitability
EPS (Most Recent Fiscal Year)($0.21)
Net Income$-18,410,000.00
Net MarginsN/A
Return on Equity-40.12%
Return on Assets-37.64%
Miscellaneous
Employees21
Outstanding Shares102,560,000
Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions
What is Catalyst Pharmaceuticals' stock symbol?
Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."
How were Catalyst Pharmaceuticals' earnings last quarter?
Catalyst Pharmaceuticals (NASDAQ:CPRX) posted its quarterly earnings data on Wednesday, March, 14th. The biopharmaceutical company reported ($0.06) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.06). View Catalyst Pharmaceuticals' Earnings History.
When is Catalyst Pharmaceuticals' next earnings date?
What price target have analysts set for CPRX?
4 equities research analysts have issued 1 year target prices for Catalyst Pharmaceuticals' stock. Their forecasts range from $5.00 to $8.00. On average, they expect Catalyst Pharmaceuticals' share price to reach $6.25 in the next year. View Analyst Ratings for Catalyst Pharmaceuticals.
What are Wall Street analysts saying about Catalyst Pharmaceuticals stock?
Here are some recent quotes from research analysts about Catalyst Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "AT-014 Conditional Approval: Further Attestation to Strategy AT-014 receives a conditional licensure from the USDA. On December 20, Aratana announced that the USDA Center for Veterinary Biologics has granted AT-014 conditional marketing approval for the treatment of canine osteosarcoma. AT-014 is a canine cancer vaccine derived from listeria that targets HER2/neu, a causative mutation of canine osteosarcoma. In pilot studies, AT-014 treatment of dogs with osteosarcoma (n=18) increased their median overall survival (mOS) to 956 days compared to 423 days for historical controls (p<0.05). Therefore, following the USDA approval we believe that AT-014 can quickly become a preferred therapeutic option for this difficult-to-treat indication. With four product approvals in two years, we believe the success of AT-014 is a further attestation of management's strategy of bringing advanced human therapies to the veterinarian market."" (12/21/2017)
- 2. According to Zacks Investment Research, "Catalyst Pharma posted narrower than expected loss in the third quarter of 2017. Earlier in 2016, the company received a refusal to file letter from the FDA in connection with the NDA for Firdapse. The company suffered a setback when it received a refusal to file letter for Firdapse from the FDA. Nevertheless, the company expects to report top-line results from its second phase III study of Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in early December 2017 and resubmit a new drug application (NDA) before the end of 2017. Catalyst has a limited number of candidates in its pipeline and is highly dependent on Firdapse’s approval for growth. Meanwhile, the company is also developing Firdapse for additional indications. The company’s share price movement shows that the stock has outperformed the industry year to date. " (11/14/2017)
Who are some of Catalyst Pharmaceuticals' key competitors?
Some companies that are related to Catalyst Pharmaceuticals include Progenics Pharmaceuticals (PGNX), Achillion Pharmaceuticals (ACHN), ObsEva (OBSV), Innate Pharma (IPHYF), MediciNova (MNOV), Zealand Pharma (ZEAL), Isotechnika Pharma (AUPH), ProMetic Life Sciences (PFSCF), Sinovac Biotech (SVA), Concert Pharmaceuticals (CNCE), Synergy Pharmaceuticals (SGYP), Depomed (DEPO), Syros Pharmaceuticals (SYRS), Cara Therapeutics (CARA), Albireo Pharma (ALBO), Kala Pharmaceuticals (KALA), Corium International (CORI) and Cytokinetics (CYTK).
Who are Catalyst Pharmaceuticals' key executives?
Catalyst Pharmaceuticals' management team includes the folowing people:
- Mr. Patrick J. McEnany, Co-Founder, Chairman, Chief Exec. Officer and Pres (Age 71)
- Ms. Alicia Grande CPA, CMA, Chief Financial Officer, Chief Accounting Officer, VP and Treasurer (Age 47)
- Dr. Steven R. Miller Ph.D., Chief Operating Officer and Chief Scientific Officer (Age 56)
- Dr. Gary Ingenito M.D., Ph.D., Chief Medical Officer and Head of Regulatory Affairs (Age 62)
- Mr. Brian Elsbernd, Sr. VP of Legal and Compliance (Age 54)
Has Catalyst Pharmaceuticals been receiving favorable news coverage?
News articles about CPRX stock have been trending positive recently, according to Accern Sentiment. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catalyst Pharmaceuticals earned a daily sentiment score of 0.25 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 44.99 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Catalyst Pharmaceuticals?
Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catalyst Pharmaceuticals' stock price today?
One share of CPRX stock can currently be purchased for approximately $2.53.
How big of a company is Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals has a market capitalization of $257.42 million. The biopharmaceutical company earns $-18,410,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Catalyst Pharmaceuticals employs 21 workers across the globe.
How can I contact Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]
MarketBeat Community Rating for Catalyst Pharmaceuticals (CPRX)
MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Catalyst Pharmaceuticals in the last 12 months. Their average twelve-month price target is $6.25, suggesting that the stock has a possible upside of 147.04%. The high price target for CPRX is $8.00 and the low price target for CPRX is $5.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.25 | $6.25 | $6.25 | $5.50 |
| Price Target Upside: | 147.04% upside | 109.73% upside | 60.67% upside | 109.92% upside |
Catalyst Pharmaceuticals (NASDAQ:CPRX) Consensus Price Target History
Catalyst Pharmaceuticals (NASDAQ:CPRX) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Catalyst Pharmaceuticals (NASDAQ:CPRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Catalyst Pharmaceuticals (NASDAQ CPRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.30%
Institutional Ownership Percentage: 54.89%
Catalyst Pharmaceuticals (NASDAQ CPRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/3/2018 | Patrick J Mcenany | Insider | Buy | 20,000 | $2.29 | $45,800.00 | |  |
| 9/5/2017 | Patrick J Mcenany | Insider | Buy | 20,000 | $2.58 | $51,600.00 | 4,471,026 | |
| 7/12/2016 | Charles B O'keeffe | Director | Buy | 20,000 | $0.81 | $16,200.00 | 432,126 | |
| 6/17/2016 | Philip H Coelho | Director | Buy | 15,000 | $0.76 | $11,400.00 | 159,987 | |
| 6/14/2016 | Donald A Denkhaus | Director | Buy | 50,000 | $0.65 | $32,500.00 | 100,000 | |
| 6/14/2016 | Patrick J Mcenany | CEO | Buy | 105,300 | $0.65 | $68,445.00 | 4,393,109 | |
| 4/26/2016 | Charles B O'keeffe | Director | Buy | 20,000 | $0.60 | $12,000.00 | 412,126 | |
| 4/26/2016 | Patrick J Mcenany | CEO | Buy | 50,000 | $0.65 | $32,500.00 | 4,287,809 | |
| 3/17/2016 | Philip H Coelho | Director | Buy | 10,000 | $1.06 | $10,600.00 | 158,287 | |
| 3/16/2016 | Charles B O'keeffe | Director | Buy | 10,000 | $1.11 | $11,100.00 | 392,126 | |
| 1/11/2016 | Steve Miller | COO | Buy | 7,933 | $1.80 | $14,279.40 | 457,687 | |
| 1/8/2016 | Charles B O'keeffe | Director | Buy | 5,000 | $1.94 | $9,700.00 | 377,126 | |
| 1/7/2016 | Donald A Denkhaus | Director | Buy | 25,000 | $2.03 | $50,750.00 | 50,000 | |
| 12/28/2015 | Patrick J Mcenany | CEO | Buy | 25,000 | $2.39 | $59,750.00 | 4,237,809 | |
| 12/23/2015 | Charles B O'keeffe | Director | Buy | 5,000 | $2.41 | $12,050.00 | 372,126 | |
| 11/19/2015 | Charles B O'keeffe | Director | Buy | 5,000 | $2.30 | $11,500.00 | 367,126 | |
| 10/23/2015 | M Douglas Winship | VP | Sell | 22,800 | $3.34 | $76,152.00 | 74,131 | |
| 10/1/2015 | Patrick J Mcenany | CEO | Buy | 10,000 | $2.81 | $28,100.00 | 4,137,262 | |
| 5/1/2015 | David D Muth | EVP | Buy | 1,700 | $3.20 | $5,440.00 | | |
| 4/30/2015 | Charles B O'keeffe | Director | Buy | 10,000 | $3.29 | $32,900.00 | | |
| 4/28/2015 | David D Muth | EVP | Buy | 2,000 | $3.55 | $7,100.00 | | |
| 4/27/2015 | Donald A Denkhaus | Director | Buy | 15,000 | $3.71 | $55,650.00 | | |
| 4/27/2015 | Patrick J Mcenany | CEO | Buy | 5,000 | $3.79 | $18,950.00 | | |
| 4/24/2015 | Charles B O'keeffe | Director | Buy | 5,000 | $3.80 | $19,000.00 | | |
| 3/27/2015 | Donald A Denkhaus | Director | Buy | 5,000 | $4.17 | $20,850.00 | | |
| 1/20/2015 | David D Muth | EVP | Buy | 21,000 | $2.96 | $62,160.00 | | |
| 1/13/2015 | Charles B O'keeffe | Director | Buy | 10,000 | $3.00 | $30,000.00 | | |
| 1/8/2015 | Patrick J Mcenany | CEO | Buy | 50,000 | $2.80 | $140,000.00 | | |
| 10/3/2014 | David D Muth | VP | Buy | 10,000 | $2.65 | $26,500.00 | | |
| 6/4/2014 | Steve Miller | COO | Buy | 100,000 | $2.17 | $217,000.00 | | |
| 5/21/2014 | Patrick Mcenany | CEO | Buy | 25,000 | $1.89 | $47,250.00 | 3,656,247 | |
| 5/19/2014 | Charles O'keeffe | Director | Buy | 10,000 | $1.83 | $18,300.00 | 192,126 | |
| 4/16/2014 | Charles O'keeffe | Director | Buy | 5,000 | $2.02 | $10,100.00 | 182,126 | |
| 2/7/2014 | Patrick Mcenany | CEO | Buy | 25,000 | $1.82 | $45,500.00 | 3,631,247 | |
| 2/5/2014 | Charles O'keeffe | Director | Buy | 10,000 | $1.81 | $18,100.00 | 177,126 | |
| 10/23/2013 | David S Tierney | Director | Buy | 8,000 | $2.03 | $16,240.00 | | |
| 10/21/2013 | Charles B O'keeffe | Director | Buy | 10,000 | $1.84 | $18,400.00 | | |
| 10/21/2013 | Patrick J Mcenany | CEO | Buy | 50,000 | $1.59 | $79,500.00 | | |
| 2/19/2013 | Patrick J Mcenany | CEO | Buy | 50,000 | $0.46 | $23,000.00 | | |
| 12/17/2012 | Patrick J Mcenany | CEO | Buy | 100,000 | $0.45 | $45,000.00 | | |
| 12/8/2012 | Biomarin Pharmaceutical Inc | Major Shareholder | Buy | 5,000,000 | $0.75 | $3,750,000.00 | | |
| 11/15/2012 | Patrick J Mcenany | CEO | Buy | 100,000 | $0.42 | $42,000.00 | | |
| 11/15/2012 | Philip H Coelho | Director | Buy | 24,000 | $0.41 | $9,840.00 | | |
(Data available from 1/1/2013 forward)
Catalyst Pharmaceuticals (NASDAQ CPRX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Analysts Anticipate Catalyst Pharmaceuticals (CPRX) Will Post Earnings of -$0.06 Per Share
www.americanbankingnews.com - April 22 at 3:16 PM |
 | Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody ...
globenewswire.com - April 21 at 8:19 AM |
 | BRIEF-Catalyst Pharmaceuticals Announces Enrollment Of First Patient In Phase 3 Trial Of Firdapse In Musk Antibody ...
www.reuters.com - April 21 at 8:19 AM |
 | Catalyst Enrolls First Patient in Phase III Firdapse Study
www.zacks.com - April 20 at 5:21 PM |
 | Your Daily Pharma Scoop: Adamas Update, Shire Bidding War, Novartis Results
seekingalpha.com - April 20 at 8:24 AM |
| Enrollment underway in late-stage study of Catalyst Pharma's Firdapse in subtype of myasthenia gravis
seekingalpha.com - April 19 at 5:40 PM |
 | Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia Gravis
finance.yahoo.com - April 19 at 8:16 AM |
| Catalyst Pharmaceuticals (CPRX) Down 7.4% Since Earnings Report: Can It Rebound?
www.zacks.com - April 14 at 8:23 AM |
| Catalyst Pharmaceuticals (CPRX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 11 at 3:17 AM |
| Analysts Expect Catalyst Pharmaceuticals (CPRX) to Announce -$0.06 Earnings Per Share
www.americanbankingnews.com - April 5 at 3:16 PM |
| Catalyst Pharmaceuticals Inc (CPRX) Insider Patrick J. Mcenany Acquires 20,000 Shares
www.americanbankingnews.com - April 3 at 10:44 PM |
| 3 Things In Biotech, April 2: Catalyst Pharm Goes, Pfizer Flows, MediciNova Woes
seekingalpha.com - April 3 at 8:23 AM |
| Catalyst Pharmaceuticals (CPRX) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 2 at 7:30 PM |
 | Catyalyst Pharma (CPRX) Announces Submission of NDA for Firdapse for Treatment of LEMS
www.streetinsider.com - March 30 at 8:23 AM |
 | Catalyst Pharmaceuticals files new drug application with FDA
www.bizjournals.com - March 29 at 5:30 PM |
| Catalyst Pharma refiles U.S. marketing application for Firdapse for LEMS; shares up 2% premarket
seekingalpha.com - March 29 at 5:30 PM |
| Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse® for Treatment of Lambert-Eaton Myasthenic Syndrome
finance.yahoo.com - March 29 at 8:27 AM |
| Catalyst Pharmaceuticals (CPRX) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - March 26 at 5:58 PM |
| UPDATE: Catalyst Pharmaceutical Partners (CPRX) PT Raised to $6 at Roth Capital Following 4Q - StreetInsider.com
www.streetinsider.com - March 20 at 8:27 AM |
| Catalyst Pharmaceuticals Inc (CPRX) Expected to Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - March 19 at 3:14 PM |
| SunTrust Banks Research Analysts Increase Earnings Estimates for Catalyst Pharmaceuticals Inc (CPRX)
www.americanbankingnews.com - March 19 at 1:54 AM |
| Catalyst Pharmaceuticals Inc (CPRX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 17 at 4:00 AM |
| Catalyst Pharmaceuticals Inc Forecasted to Earn FY2022 Earnings of $0.84 Per Share (CPRX)
www.americanbankingnews.com - March 16 at 4:21 PM |
| Catalyst Pharmaceuticals (CPRX) Downgraded to "Strong Sell" at BidaskClub
www.americanbankingnews.com - March 16 at 2:10 PM |
 | Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress - Nasdaq
www.nasdaq.com - March 16 at 8:20 AM |
| Catalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 16 at 8:20 AM |
| Catalyst Pharmaceuticals (CPRX) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - March 15 at 3:02 PM |
| Clinical Hold On IGNITE DMD Douses SLDB, PTI Awaits Data In Q2, CPRX On Watch - Nasdaq
www.nasdaq.com - March 15 at 8:16 AM |
| Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate ... - GlobeNewswire (press release)
globenewswire.com - March 15 at 8:16 AM |
| Catalyst Pharmaceuticals (CPRX) Issues Quarterly Earnings Results, Meets Expectations
www.americanbankingnews.com - March 15 at 7:56 AM |
| Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 14 at 7:07 PM |
| When Will Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Breakeven?
finance.yahoo.com - March 14 at 7:07 PM |
| Catalyst Pharmaceuticals Announces Date and Time Change for ... - Nasdaq
www.nasdaq.com - March 13 at 8:25 AM |
| Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call ... - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:25 AM |
 | Carbon Disulfide Market Worth $165.1 Million By 2025 | CAGR: 2.4% : Grand View Research, Inc.
www.prnewswire.com - March 12 at 6:40 PM |
| Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast
finance.yahoo.com - March 12 at 9:02 AM |
| Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results Conference Call and Webcast on Thursday, March 15th, 2018
finance.yahoo.com - March 8 at 8:23 AM |
| Catalyst Pharmaceuticals (CPRX) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - March 6 at 2:32 AM |
| Zacks: Brokerages Expect Catalyst Pharmaceuticals Inc (CPRX) Will Post Earnings of -$0.06 Per Share
www.americanbankingnews.com - March 2 at 7:42 PM |
| Catalyst Pharmaceuticals Inc (CPRX) Position Boosted by Broadfin Capital LLC
www.americanbankingnews.com - March 2 at 5:08 AM |
| Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018 - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:15 AM |
| Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018 - Nasdaq
www.nasdaq.com - February 28 at 8:17 AM |
| Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018
finance.yahoo.com - February 28 at 8:17 AM |
| EAM Investors LLC Acquires Shares of 1,042,519 Catalyst Pharmaceuticals Inc (CPRX)
www.americanbankingnews.com - February 27 at 3:00 PM |
| Catalyst Pharmaceuticals Inc (CPRX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - February 20 at 3:28 AM |
| Catalyst Pharmaceutical (CPRX) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 3:43 PM |
| Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse®
finance.yahoo.com - February 12 at 9:44 AM |
| Catalyst Pharmaceuticals to Present at Two Upcoming Investor Conferences
finance.yahoo.com - February 7 at 9:34 AM |
| Catalyst Pharmaceuticals Inc (CPRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 26 at 3:24 AM |
| Contrasting TESARO (TSRO) & Catalyst Pharmaceuticals (CPRX)
www.americanbankingnews.com - January 25 at 10:34 AM |
Catalyst Pharmaceuticals (NASDAQ:CPRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Catalyst Pharmaceuticals (NASDAQ:CPRX) Income Statement, Balance Sheet and Cash Flow Statement
Catalyst Pharmaceuticals (NASDAQ CPRX) Stock Chart for Monday, April, 23, 2018
Loading chart…
